Table 2.
Comparison of the clinical background factors of the patients, separated according to their baseline serum albumin concentrations
| Parameter | Albumin below 4.0 g/dl |
Albumin 4.0 g/dl or more |
|||||
|---|---|---|---|---|---|---|---|
| Treatment group | Control group | p value* | Treatment group | Control group | p value* | ||
| Number | 4 | 11 | 26 | 21 | |||
| Gender (male) | 1 (25.0%) | 6 (54.5%) | 0.5692 | 14 (51.8%) | 13 (48.1%) | 0.8307 | |
| Age | 68.1 ± 1.2 | 63.2 ± 10.9 | 0.4016 | 54.5 ± 13.2 | 58.0 ± 9.1 | 0.2974 | |
| BMI | 23.4 ± 0.2 | 22.5 ± 1.5 | 0.4454 | 23.2 ± 3.5 | 23.1 ± 3.0 | 0.9625 | |
| AST (U/L) | 73.0 ± 17.0 | 66.1 ± 30.2 | 0.7664 | 62.6 ± 26.1 | 54.7 ± 20.0 | 0.2771 | |
| ALT (U/L) | 96.6 ± 65.5 | 56.8 ± 27.3 | 0.1119 | 88.7 ± 38.4 | 65.3 ± 38.0 | 0.0524 | |
| Platelet count (×104/µL) | 10.5 ± 3.0 | 15.2 ± 5.7 | 0.1400 | 15.9 ± 4.1 | 15.8 ± 5.3 | 0.9081 | |
| Zinc concentration (µg/dl) | 55.0 ± 11.4 | 51.7 ± 10.5 | 0.6097 | 60.6 ± 8.7 | 56.0 ± 9.6 | 0.0879 | |
| Albumin (g/dl) | 3.7 ± 0.3 | 3.8 ± 0.1 | 0.3627 | 4.2 ± 0.2 | 4.2 ± 0.2 | 0.8351 | |
| Observation period (year) | 7.4 ± 3.8 | 5.8 ± 2.4 | 0.3437 | 8.7 ± 2.0 | 7.7 ± 3.2 | 0.2266 | |
*p<0.005. Mann-Whitney U test, chi-square test. Treatment group: patients with polaprezinc administration. Control group: patients without polaprezinc administration. The study subjects were grouped into those with baseline serum albumin concentrations below 4.0 g/dl in and those with serum albumin concentrations of 4.0 g/dl or more. Comparison of the clinical characteristics of patients with and without polaprezinc administration.